VPT:CC - Ollie Hinkle Heart Foundation will Introduce Ventripoint's AI-Heart-Imaging Diagnostic Technology to America's Hospitals
(TheNewswire)
Toronto, Ontario – TheNewswire - December 05, 2023 –One of the United States’ leading foundations, the Ollie HinkleHeart Foundation (OHHF), has selected Ventripoint’s AI-poweredheart-imaging technology as one of three artificial intelligencesystems it will be presenting to U.S. hospitals.
Ventripoint Diagnostics Ltd. (" Ventripoint " orthe " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) haspioneered an AI technology that transforms ultrasound scans intoMRI-quality images of the heart in minutes, at a fraction of the cost,making it a new alternative to MRI heart scans.
Ventripoint’s FDA-cleared AI-heart-imaging technologycan be easily used with all brands of cardiac ultrasound equipment.Technicians and medical staff can be trained on the unit inapproximately two hours.
“We think Ventripoint is a game-changer for childrenwith heart disease,” said Beth Rumack, the Chief Operating Officerof the OHHF. “You no longer need to take a child down to an MRIsuite, which entails a whole team of technicians and often meanshaving to put the child under anesthesia, so they don’t move duringthe MRI scan.
“With Ventripoint, you just put a sensor on thechild’s chest,” added Rumack, who is also a cardiac nursepractitioner and former hospital administrator. “You can do the scanin the child’s hospital room, even in a cardiologist’s office, andthe results are available in minutes, not days. And you can take ascan safely, as often as you need.”
OHHF is bringing together 13 U.S. hospital partnersinto its Take Heart program, with 30 more expected to join, to promotenew technologies and patient care approaches to heart health care,particularly for children and their families. It has selected threecompanies featuring AI technologies: Ventripoint, the clinical datasoftware platform Etiometry, and the remote pediatric monitoringplatform Locus Health.
“We want to introduce Ventripoint to all our hospitalpartners, to make it a standard of care,” said Rumack.“ Ventripoint is the only AI technology likethis in this category. There’s nobody else doing this. TheirArtificial Intelligence approach to heart scans is pushing health carein a new direction, offering an inexpensive and rapid alternative tomost MRI heart scans.”
Dr. Alvira Macanovic, Ventripoint’s President andCEO, welcomed the strategic partnership: “We are proud of theendorsement of the Ollie Hinkle Heart Foundation. OHHF aligns with Ventripoint’s core mission of helpingpatients with heart disease, as well as their families. We arecommitted to furthering Ollie’s legacy by providing a less invasiveand smarter treatment option. This partnershipwill advance the introduction of Ventripoint into U.S.hospitals.”
Jenn and Mark Hinkle, who lost their son to heartdisease, are known for their advancement and funding of newtechnologies and innovative approaches to improving the care andoutcomes for children facing heart disease.
"We're excited by the work being done atVentripoint to advance the diagnostic capability and technology forthe pediatric heart community,” said Jenn Hinkle. “Because Ollie had a pacemaker, he wasn't a candidate foran MRI. Had something like the VMS+ been around when Ollie was alive,his cardiac team would have had access to a clearer picture of whatwas going on with his heart during those critical moments leading upto his death, and his outcome may have been different.”
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
About the Ollie Hinkle HeartFoundation
Ollie Hinkle died due to congenital heart disease (CHD)at 13 months old. Mark and Jenn Hinkle channelled their grief into theOllie Hinkle Heart Foundation (OHHF) by taking their love for Ollieand the love given to them by family and friends to pay it on to heartfamilies whose struggles they knew first-hand. During Ollie’s life,the Hinkles observed the ineffective nature of cardiac care, whichleaves families to endure and navigate mounting unmet needs alone.This experience led to a mission to transform the future of pediatricheart care by uniting families and clinicians to address basic socialneeds through Community Outreach, mental healthcare access throughOllie’s Branch, support for Technology and Research to improveoutcomes, and collective community building through Take Heart.
For further information, pleasecontact:
Jonathan Robinson
JRobinson@oakhillfinancial.ca
416-669-1001
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should", "believe", "plans","intends'' and similar expressions are intended to identifyforward-looking information or statements. The forward-lookingstatements and information are based on certain key expectations andassumptions made by the Company. Although the Company believes thatthe expectations and assumptions on which such forward-lookingstatements and information are based are reasonable, undue relianceshould not be placed on the forward-looking statements and informationbecause the Company can give no assurance that they will prove to becorrect.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to several factors andrisks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether becauseof new information, future events or otherwise, unless so required byapplicable securities laws.
Copyright (c) 2023 TheNewswire - All rights reserved.